Evolent Health, Inc. (NYSE:EVH) Receives $18.38 Consensus Target Price from Analysts

Evolent Health, Inc. (NYSE:EVH) has been assigned an average rating of “Buy” from the thirteen brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $17.92.

EVH has been the topic of several research analyst reports. Oppenheimer lowered their target price on shares of Evolent Health from $28.00 to $18.00 and set an “outperform” rating on the stock in a research note on Friday, January 24th. Truist Financial dropped their target price on Evolent Health from $20.00 to $15.00 and set a “buy” rating on the stock in a report on Wednesday, January 22nd. Stephens decreased their price target on Evolent Health from $16.00 to $12.00 and set an “equal weight” rating for the company in a research note on Tuesday, January 21st. BTIG Research dropped their price objective on Evolent Health from $36.00 to $29.00 and set a “buy” rating on the stock in a research note on Tuesday, December 3rd. Finally, Canaccord Genuity Group dropped their target price on shares of Evolent Health from $23.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd.

Hedge Funds Weigh In On Evolent Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State of Wyoming acquired a new stake in shares of Evolent Health during the 4th quarter worth approximately $95,000. Sea Cliff Partners Management LP bought a new position in shares of Evolent Health in the fourth quarter valued at approximately $9,338,000. Silvercrest Asset Management Group LLC increased its position in Evolent Health by 37.3% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 1,371,053 shares of the technology company’s stock valued at $15,424,000 after acquiring an additional 372,793 shares in the last quarter. Raiffeisen Bank International AG bought a new position in shares of Evolent Health in the fourth quarter worth about $988,000. Finally, Redwood Investment Management LLC acquired a new position in shares of Evolent Health during the fourth quarter worth approximately $468,000.

Evolent Health Trading Up 0.7 %

NYSE:EVH opened at $10.09 on Friday. The company has a market cap of $1.18 billion, a PE ratio of -11.09 and a beta of 1.45. The business’s 50 day moving average is $10.82 and its two-hundred day moving average is $19.04. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. Evolent Health has a 52 week low of $9.45 and a 52 week high of $35.00.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.